oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Search Results: 1 - 10 of 674 matches for " Radheshyam Naik "
All listed articles are free for downloading (OA Articles)
Page 1 /674
Display every page Item
Analysis of Use and Outcomes of Peripherally Inserted Central Catheter (PICC-Line) in Hemato-Oncological Patients  [PDF]
Sulav Sapkota, Radheshyam Naik
Journal of Cancer Therapy (JCT) , 2018, DOI: 10.4236/jct.2018.91005
Abstract: Aims: To audit the use and outcomes of using PICC lines in hemato-oncological patients. Objectives: To study the demographics of patients: ?studying the use of PICC line in hemato-oncological patients; studying the rate of complications in PICC line; studying the cause of early removal of PICC line. Methods: All PICCs inserted in adult hemato-oncological patients in Hematology and Medical Oncology Department of Health Care Global (HCG) Hospital were studied prospectively, as per the proforma, till PICCs were removed or patient expired and the pattern of complications were noted. Results: Eighty-four PICCs were inserted over a period of initial nine months and followed for a total of 1 year with three months post insertion duration for a total of 10,868 catheter-days (mean of 129 days i.e. 4.3 months, range: 1 to 288 days). The most common indication for PICC was chemotherapy (100%). Among them
Efficacy Study of Metronomic Chemotherapy in Metastatic Triple Negative Breast Cancer and Correlation with VEGF, TSP Levels  [PDF]
B. J. Srinivasa, Lalkota Prakash Bhanu, Vidhya H. Veldore, R. Raghavendra, Radheshyam Naik
Advances in Breast Cancer Research (ABCR) , 2018, DOI: 10.4236/abcr.2018.72007
Abstract: Background: Treatment refractory metastatic breast cancer patients are at best treated palliatively. We evaluated the effects of metronomic chemotherapy on survival outcomes in this population. Methods: Twenty eight subjects with treatment refractory (n = 21) and treatment naive (n = 7) MBC were included in an open label single arm efficacy study of metronomic chemotherapy. Patients were given a chemotherapy regimen of Tab. Cyclophosphamide 50 mg once daily and Tab. Methotrexate 2.5 mg twice in a week over a minimum period of 3 months or until the progression of their disease whichever was earlier. Monitoring of serum VEGF and Thrombospondin levels were done to correlate the response rates. Data were analysed using chi square test for proportions and Kaplan Meir Survival analysis. Results: The mean age of the study population was 51.5 ± 14.2 years. The mean duration of metronomic chemotherapy was 123.89
Clinical Profile and Results in Cancers Treated with Nivolumab: A Single Centre Study  [PDF]
B. J. Srinivasa, Bhanu Prakash Lalkota, Sulav Sapkota, Vinu Sarathy, Nithin Bayas, Radheshyam Naik
Open Journal of Immunology (OJI) , 2018, DOI: 10.4236/oji.2018.84007
Abstract: Introduction: Immunotherapy is also called as biologic therapy or bio-therapy. Immunotherapy is quickly becoming an important component in the multipronged approaches being developed to treat certain forms of cancer. The goal of immunotherapy is to strengthen the body’s own natu-ral ability to combat cancer by enhancing the effectiveness of the immune system. This study tries to compile response rates and side effect profile of Nivolumab. Methods: Patients with performance status of 3 or less than 3, who failed on 2 or more lines of therapy except melanoma and have received minimum 3 cycles of Nivolumab were taken in to this study. Study subjects followed for minimum of 3 cycles for assessment. Each patient received 240 mg of Nivolumab once in 15 days for 3 - 6 cycles. Results: The median age of 20 patients was 53 years (26 - 79 yrs). 18 patients were male and 2 patients were female. Progressive disease (PD) was observed in 12 patients with immunotherapy treatment and partial response (PR) was observed in 3 patients, and stable disease (SD) in 5 patients. Conclusion: This is one of the Indian study mainly reporting experiences with Nivolumab. Large sample size is required to conclude about the efficacy of the study. Nivolumab is more tolerated in Indian patients compared to other reported studies.
Case of fosphenytoin induced acute cerebellar dysfunction and pituitary bleed causing central diabetes insipidus in a case of AML M2 during allogenic hematopoietic stem cell transplant
Eriat Govind,Radheshyam Naik,Srinivas BJ,Intezar Mehdi
International Journal of Pharmacology and Clinical Sciences , 2012,
Abstract: Neuroprotectors such as phenytoin, fosphenytoin, clonazepam or levetiracetam are often used prior conditioning regimen to prevent seizures caused due to busulfan, during bone marrow transplant. Fosphenytoin and levetiracetam are used instead of phenytoin as they are readily soluble and do not need a vehicle such as polyethylene glycol or ethanol which increases risk of tissue and cardio toxicity. We report a case of acutetoxicity in the form of cerebral bleed during intravenous administration of fosphenytoin and its subsequent management in patient undergoing busulfan treatment prior to allogenic transplant.
Klebsiella pneumoniae Carbapenamase (KPC) Outbreak in a Multispeciality Cancer Hospital—An Emerging Superbug  [PDF]
Sulav Sapkota, Shobha K. Ganesan, Mona Priyadarshini, Shobha Savitha A., Radheshyam Naik
Advances in Infectious Diseases (AID) , 2019, DOI: 10.4236/aid.2019.93012
Abstract: Aim: To identify, analyse and control the outbreak of Carbapenamase producing Klebsiella pneumoniae. Objectives: 1) To detect multidrug resistant K. pneumoniae at the earliest and isolate patients. 2) To find out the predisposing causes for the occurrence of this outbreak. 3) To break the chain of infection transmission. 4) To reduce the risk of Hospital acquired infections. Methods: This retrospective study along with the surveillance was conducted from January 2017 to March 2017 at HCG multispecialty cancer hospital, Bangalore, India. Results: Total 15 patients were diagnosed with KPC infection during the first month of the study period. Those affected were mostly Male patients (73%), admitted in ICU (73%) for further treatment. In our study, the incidence of KPC infection was mostly found with bloodstream infections (60%), mostly seen in those with central lines (80%) followed by patients on ventilatory support (66%). Before the outbreak of KPC infection, all the patients (100%) had already been treated with higher antibiotics including Carbapenems. In our study, only nine out of fifteen patients (60%) could be salvaged with treatment and were discharged. Conclusions: Hospital Infection Control Committee’s regular screening and the training of healthcare professionals are vital for the control of the outbreak.
Layout Design of LC VCO with Current Mirror Using 0.18 µm Technology  [PDF]
Namrata Prasad, Radheshyam Gamad
Wireless Engineering and Technology (WET) , 2011, DOI: 10.4236/wet.2011.22014
Abstract: This paper presents a new design of complementary oxide semiconductor voltage controlled oscillator (CMOS VCO) for improve tuning range and phase noise with low power consumption. Design is area efficient and easy to implement. Design is carried out in cadence and schematic editor using 180 nm technology. Simulation is done and performance results are reported. Results have been compared with earlier published work and improvements are obtained in this work.
Design of Low Power and High Speed CMOS Comparator for A/D Converter Application  [PDF]
Shubhara Yewale, Radheshyam Gamad
Wireless Engineering and Technology (WET) , 2012, DOI: 10.4236/wet.2012.32015
Abstract: This paper presents an improved method for design of CMOS comparator based on a preamplifier-latch circuit driven by a clock. Design is intended to be implemented in Sigma-delta Analog-to-Digital Converter (ADC). The main advantage of this design is capable to reduce power dissipation and increase speed of an ADC. The design is simulated in 0.18 μm CMOS Technology with Cadence environment. Proposed design exhibits good accuracy and a low power consumption about 102 μW with operating sampling frequency 125 MHz and 1.8 V supply. Simulation results are reported and compared with earlier work done and improvements are observed in this work.
Design of a New Serializer and Deserializer Architecture for On-Chip SerDes Transceivers  [PDF]
Nivedita Jaiswal, Radheshyam Gamad
Circuits and Systems (CS) , 2015, DOI: 10.4236/cs.2015.63009
Abstract: The increasing trends in SoCs and SiPs technologies demand integration of large numbers of buses and metal tracks for interconnections. On-Chip SerDes Transceiver is a promising solution which can reduce the number of interconnects and offers remarkable benefits in context with power consumption, area congestion and crosstalk. This paper reports a design of a new Serializer and Deserializer architecture for basic functional operations of serialization and deserialization used in On-Chip SerDes Transceiver. This architecture employs a design technique which samples input on both edges of clock. The main advantage of this technique which is input is sampled with lower clock (half the original rate) and is distributed for the same functional throughput, which results in power savings in the clock distribution network. This proposed Serializer and Deserializer architecture is designed using UMC 180 nm CMOS technology and simulation is done using Cadence Spectre simulator with a supply voltage of 1.8 V. The present design is compared with the earlier published similar works and improvements are obtained in terms of power consumption and area as shown in Tables 1-3 respectively. This design also helps the designer for solving crosstalk issues.
Impact of MGMT Promoter Methylation as a Prognostic Marker in Patients with High Grade Glioma: A Single-Center Observational Study  [PDF]
Vinu Sarathy, Srinivasa Belagutty Jayappa, Bhanu Lalkota, Kiran Pura Krishnamurthy, Vishal Kulkarni, Samuel Luke Koramati, Nasiruddin Mohammad, Radheshyam Naik
Journal of Cancer Therapy (JCT) , 2019, DOI: 10.4236/jct.2019.1010068
Abstract: Objectives: 1) To correlate the methylation status of the O-6-methylguanine-DNA-methyltransferase (MGMT promoter gene) and response to alkylating agent-based treatment in high-grade gliomas. Background: The MGMT gene is epigenetically silenced by promoter hypermethylation in gliomas and this modification has emerged as a relevant predictor of therapeutic response. Methods: 20 cases of high-grade glioma were analyzed for MGMT promoter methylation by methylation-specific PCR. Response to treatment and overall survival data were recorded and data analysed. Results: MGMT promoter methylation was found in 60% of gliomas by methylation-specific PCR. The mean survival time of glioblastoma patients submitted to adjuvant therapy was significantly higher among patients with MGMT promoter methylation (P = 0.035) and methylation status was an independent predictive factor that was associated with improved prognosis. Discussion and Conclusion:
Design of a CMOS Optical Receiver Front-End Using 0.18 μm Technology  [PDF]
Ajay Shukla, Radheshyam Gamad, Rohan Raikwar
Wireless Engineering and Technology (WET) , 2013, DOI: 10.4236/wet.2013.41007
Abstract:

This paper reports design of a CMOS optical receiver front-end using 0.18 μm technology. Design process is current associated with photodiode using trans-impedance amplifier (TIA) for wide bandwidth, high gain, low input referred noise and wide dynamic range. The Automated Gain Control (AGC) voltage is used to provide variable gain for multilevel signals. This design is simulated in 0.18 μm UMC technology for the performance analysis. The best simulation results are reported the maximum TIA gain of 67.26 dB? at 0 V AGC followed by a post amplifier gain of 86.70 dB?. The bandwidth range is 7.03 GHz to 11.5 GHz corresponding to 0 - 3 V AGC respectively. The input referred noise level value is 43.86 pA/√Hz up to 10 GHz frequency. In addition authors have obtained the common mode rejection ratio (CMRR) is 72.42 dB and rectified group delay is 144.48 ps. Verification of the design, reported results are compared with earlier published work and improvements obtained in the present results.

Page 1 /674
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.